Douglas A Stewart (Douglas Stewart)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Multiple Myeloma

Epstein Barr Virus

Hodgkin Lymphoma

Top Venues

Leukemia & lymphoma

European journal of haematology

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Douglas A Stewart, John G Kuruvilla, David Lee, Jill J Dudebout, Neil Chua, Jean-François Larouche, Tara Baetz, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Graeme Fraser, Pamela Skrabek, Vishal Kukreti, Jesse Kelly, Annette E Hay, Lois E Shepherd, Bingshu E Chen, Michael Crump
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP. British journal of haematology (2024)
Irina Amitai, Kim Roos, Iran Rashedi, Yidi Jiang, Kathryn Mangoff, Gail Klein, Nicholas Forward, Douglas A Stewart, Pierre Laneuville, Isabelle Bence-Bruckler, Joy Mangel, George A Tomlinson, Neil L Berinstein
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL. European journal of haematology (2023)
Farheen Manji, Robert Puckrin, Douglas A Stewart
Novel synthetic drugs for the treatment of non-Hodgkin lymphoma. Expert opinion on pharmacotherapy 22 (11) (2021)
Nikki Blosser, Jennifer Jupp, Patrick Yau, Douglas A Stewart
Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. Clinical pharmacokinetics 59 (1) (2021)
Tom Dunne, Douglas A Stewart, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar J Bahlis, Victor H Jimenez-Zepeda
Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic. Leukemia & lymphoma (2021)
Chandini M Thirukkumaran, Zhong Qiao Shi, Gerard J Nuovo, Joanne Luider, Karen A Kopciuk, Yuan Dong, Ahmed A Mostafa, Satbir Thakur, Kathy Gratton, Ailian Yang, Alex C Chin, Matt C Coffey, Victor H Jimenez-Zepeda, Douglas A Stewart, Marta Chesi, Peter Leif Bergsagel, Don Morris
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood advances 3 (5) (2020)
Jiajia Liu, Douglas A Stewart, Amelie Fontaine, Anthea C Peters, Isabelle Fleury, Luigina Mollica, Anca Prica, Rena Buckstein, Laurie Sehn, Aixiang Jiang, John Kuruvilla, Diego R Villa
Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. Leukemia & lymphoma 61 (10) (2020)
Robert B Basmadjian, Winson Y Cheung, Douglas A Stewart
Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes. Breast cancer : basic and clinical research 13 (2019)
Mita Manna, Richard Lee-Ying, Gwynivere A Davies, Colin Stewart, Danielle H Oh, Anthea C Peters, Douglas A Stewart
Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leukemia & lymphoma 60 (1) (2018)